ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DNLI vs RLAY // FREE CASH FLOW YIELD

Denali Therapeutics Inc. (NASDAQ) VS. Relay Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: DNLI 1 — RLAY 3
▲ FREE CASH FLOW YIELD LEADER: RLAY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DNLI VS. RLAY) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DNLI RLAY SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -13.67% -5.53% -8.14 RLAY /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 53.40% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 10.87 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 RLAY /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.0 43.5 +1.50 DNLI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.01B $3.79B -$772.0M RLAY /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DNLI REV RLAY REV DNLI GROSS % RLAY GROSS % DNLI FCF RLAY FCF
FY 2025 $1.55B $15.4M — — -$422.1M -$235.9M
FY 2024 $1.36B $10.0M — — -$363.6M -$251.1M
FY 2023 $330.5M $25.5M — — -$358.0M -$300.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DNLI // BETA —
RLAY // BETA —